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Abstract
Over the past two decades, DNA samples from thousands of families have been collected and
genotyped for linkage studies of common complex diseases such as type 2 diabetes, asthma and
prostate cancer. Unfortunately, little success has been achieved in identifying genetic susceptibility
risk factors through these considerable efforts. However, significant success in identifying common
disease risk-associated variants has been recently achieved from genome-wide association (GWA)
studies using unrelated case-control samples. These GWA studies are typically performed using
population-based cases and controls that are ascertained irrespective of their family history for the
disease of interest. Few genetic association studies have taken full advantage of the considerable
resources that are available from the linkage-based family collections despite evidence showing cases
that have a positive family history of disease are more likely to carry common genetic variants
associated with disease susceptibility. Herein, we argue that population stratification is still a concern
in case-control genetic association studies, despite the development of analytic methods designed to
account for this source of confounding, for a subset of SNPs in the genome, most notably those SNPs
in regions involved with natural selection. We note that current analytic approaches designed to
address the issue of population stratification in case-control studies cannot definitively distinguish
between true and false associations and we argue that family-based samples can still serve an
invaluable role in following-up findings from case-control studies.
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Recent successes in identifying disease risk associated variants using genome-wide association
(GWA) studies have demonstrated the power of this approach in discovering novel risk factors.
Interestingly, many of these genetic risk variants were identified in study populations
consisting of patients with specific diseases and a common set of controls from the general
population (1), rather than in well-matched case-control populations where cases and controls
are ascertained from the same well defined populations. The fact that many of these associations
can be consistently replicated in other study populations appears to relieve concern about
population stratification, a phenomenon in genetic association studies where differences in
allele or genotype frequencies at a particular polymorphism between samples of cases and
controls are due to differences in ethnic origins between the two samples, rather than a real
effect of the variation at the polymorphism on disease risk. However, by carefully examining
genetic association findings of several recent studies, we found that population stratification
may manifest in different forms and still be a concern in genetic association studies for a subset
of SNPs in the genome. We believe that proper recognition of the potential problem, utilization
of appropriate study designs and analytical tools to address this potential confounding, and
cautious interpretation of association results are still critical issues in genetic association
studies. We argue that family-based association studies, which take advantage of previously
collected family samples, can play an important role in assessing the relationship between
genetic variants and disease and may be particularly valuable for following up results from
case-control studies.
Large geographic variation in allele frequencies for a subset of SNPs in the
genome
Considerably heterogeneous allele frequencies are observed among people from different
geographic regions for a subset of SNPs in the genome. As demonstrated in the Wellcome
Trust Case Control Consortium (WTCCC) GWA study where allele frequencies of SNPs across
the genome were compared among ∼17,000 subjects from 12 broad geographical regions
across Great Britain (1), SNPs in several genomic regions had highly significant differences
in allele frequencies (Fig 1A), including a number of regions not previously implicated by past
studies. Some of the differences reached genome-wide significance levels (P < 10−7), for
example SNPs at 2q21.3, 4p14, 6p21. Spurious statistical differences in allele frequencies
between cases and controls can occur for SNPs at these regions if they are not well matched
in terms of ancestry. While the impact of ancestral variation on genetic association studies can
be minimized with appropriate study designs and analytical adjustment, it may be difficult to
remove this confounder in all situations, such as when there are strong differences in allele
frequencies among SNPs in genomic regions under selective pressure between geographically
neighboring populations or when the same factors play a role in contributing to both
geographical variation in allele frequencies and disease risk.
For example, allele frequencies of multiple SNPs at 4p14 near the TLR-6-1-10 gene cluster
were found to be significantly different among subjects from the 12 broad geographical regions
across Great Britain in the WTCCC study; P values of ∼10−40 were found when using 11-d.f.
tests (1). It is hypothesized that these differences may reflect the outcome of natural selection
due to the roles of these genes in preventing a variety of infectious diseases (2). In the meantime,
sequence variants in the TLR6-1-10 gene cluster have been reported to be associated with
prostate cancer risk in a well matched case-control study population from Sweden by our group
(3). Several SNPs were significantly associated with prostate cancer risk in a population-based
case-control study from Sweden that included 2,887 cases and 1,715 controls. For example,
we found a SNP at 5′UTR of TLR1 gene (rs5743551) was significantly associated with prostate
cancer risk; the minor allele frequency was 0.254 in cases and 0.221 in controls, P = 0.0009
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(Fig 1B). Further examination of this SNP revealed that the significant association was
primarily driven by subjects from the central part of Sweden, P = 0.002. The association was
in the same direction but was not statistically significant among subjects from the northern part
of Sweden. The difference in strength of association for this SNP in these two regions could
be partially explained by the large observed geographic variation in minor allele frequency.
The difference in the minor allele frequency observed in these two regional populations was
significantly different both before and after accounting for prostate cancer (P < 0.001 and P =
0.01, respectively). Although the SNP remained significant after adjusted for geographic region
(P = 0.004), we cannot completely remove the potential confounding effect of geographic
variation because there may be additional hidden population structure within these regions.
Considering that TLR6-1-10 sequence variants may play a role in both prostate cancer risk
(4,5) and natural selection (2), it is difficult to dissect true prostate cancer association from
confounding using frequency tests, even in this relatively homogeneous and well matched
Swedish study population.
Variable ancestry proportions in cases and controls within a race group
It is well known that false positive associations may occur in genetic association studies if
samples of cases and controls are from different populations and if the rate of disease is different
in the two populations. The problem likely also exists when cases and controls are ostensibly
from the same race and ethnic group but have different proportions of sub-race or sub-ethnic
ancestry. For example, African Americans from different parts of the U.S. have various levels
of west African, east African, and European ancestry, while European Americans in the U.S.
have various levels of southern or northern European ancestry (6). The magnitude of this
potential problem depends on the complexity and degree of admixture among sub-groups,
differences in disease risk and prevalence between the sub-groups, and differences in allele
frequencies for SNPs in the genome (global) and in a specific region of genome (local) between
these sub-groups. Recent results of association studies of multiple independent sequence
variants at 8q24 and prostate cancer risk exemplify the complexity of this potential problem.
Association of prostate cancer risk with 8q24 variants was initially discovered in a fine mapping
study of a prostate cancer linkage region at 8q24 among two case-control study populations
from Iceland (7). It includes a SNP, rs1447295, and multiple other variants that are in strong
linkage disequilibrium (LD) with this SNP. This locus was independently confirmed in all
published study populations, including those from Sweden and the U.S (7), Multiethnic cohort
(MEC) (8), Australia (9), Mayo Clinics (10), Breast and Prostate Cancer Cohort Consortium
(11), and King County of Washington (12). This locus was also implicated as one of the
strongest prostate cancer associated regions in three GWA studies (13-16). Interestingly, in
addition to the locus rs1447295 at 128,554,220 bp (referred to as Region 1 of 8q24), two
additional loci that are within 500 Kb proximal to Region 1 were found to be independently
associated with prostate cancer risk (13,14,17). One of these two regions includes the SNP
rs6983267 at 128,510,352 bp (referred to as Region 3 of 8q24) and the other includes a SNP
rs16901979 at 128,194,098 bp (referred to as Region 2 of 8q24). Independent support for
association of these three regions at 8q24 with prostate cancer risk was also observed in a
hospital based case-control study from the Johns Hopkins Hospital (18). While these consistent
findings strongly suggest the presence of true disease causal variants in this region, several
interesting observations suggest that we need to take residual population stratification into
consideration in order to appropriately interpret the observed associations at multiple
independent regions of 8q24.
One interesting observation is that all of the ‘risk alleles’ for SNPs at the three 8q24 regions
have higher estimated frequencies in African study populations; allele A of rs1447295 at
Region 1, allele T of rs6983267 at Region 3, and allele A of rs16901979 at Region 2 were all
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found to be more common in prostate cancer cases than in controls of European Americans
(13-18). All of these risk alleles have considerably higher frequencies in the African population
(YRI) than the European population (CEU); their frequencies (YRI/CEU) for these three SNPs
in Regions 1, 3, and 2 are 0.54/0.02, 0.98/0.46, and 0.34/0.07, respectively. The implication
of these large differences in allele frequencies between YRI and CEU samples is that if prostate
cancer cases in general have a higher proportion of African ancestry than controls, these SNPs
would be particularly susceptible to be erroneously statistically associated with prostate cancer
risk due to population stratification given the increased risk for prostate cancer in men of
African descent.
Data from an admixture mapping study in African American prostate cancer cases and controls
does indicate that African American prostate cancer cases have a higher proportion of African
ancestry than controls. As shown in Figure 2, the proportion of African ancestry was estimated
at each region of the genome among African American prostate cancer cases and controls in
the U.S. (8,17). In the samples considered, African American prostate cancer cases have a
higher proportion of African descent across the entire genome than do African American
controls. The mean proportion of African ancestry in the genome (global) was significantly
higher in these cases (78.2%) than in controls (74.8%), P < 0.001. The difference was largest
(> 7%) at a local region of 8q24 (126-129 Mb). These results, if confirmed, may have several
important implications. The systematic difference in estimated proportion of African Ancestry
suggests these African American samples are not ideally matched to control the effects of
population stratification. The higher African ancestry proportion across the entire genome in
cases than in controls suggests that many SNPs may have different allele frequencies between
cases and controls due to population stratification. Correcting for this consistently observed
difference in proportion of African Ancestry across the genome using appropriate analytic
techniques on available genetic marker data is necessary to maintain unbiased association tests
given the systematic differences in allele frequencies between European and African
populations.
Another observation is that there is considerable variation in allele frequencies for the 8q24
risk variants among European subjects. As shown in Table 1, the allele frequencies for
rs1447295 at Region 1 differed considerably among different European study populations. The
frequency of the risk allele A ranges from 0.07 in a French population (Southern Europe) to
0.17 in a Finnish population (Northern Europe). However, it is striking to note that prostate
cancer cases have a consistently higher frequency than controls within each of these study
populations. One of the most favorable interpretations of these results is that the consistent
association finding is due to true prostate cancer risk loci at 8q24. Alternatively, the observed
association could also be due to systematic population stratification. If prostate cancer cases
in each of these study populations have higher proportions of African ancestry than the controls,
then we would expect to observe consistently higher frequencies of these risk alleles in cases
than in controls. Unfortunately, there is a lack of data at this time for estimating African
proportions among European prostate cancer cases and controls.
Analytic adjustment for case-control association tests
We have presented two scenarios where population stratification may confound results and
compromise the interpretation of genetic association studies. As our knowledge about genetic
variations among different human populations improves, we will have a better appreciation of
the various forms and extent of population stratification on genetic association studies.
Analytical methods and study designs that address subtle and complex population stratification
are needed to address these concerns.
Lange et al. Page 4













Currently, several methods are available to adjust for potential population stratification. These
methods include genomic control (19), structured association (20,21), and principal
components analysis (22). All three methods have been demonstrated to reduce the impact of
population stratification in genetic association studies. In addition, all three procedures require
the additional genotyping of a sizable number of genetic markers, preferably not in linkage
disequilibrium, that are hypothesized not to be associated with the trait under study. Genomic
control corrects for stratification by adjusting association test statistics at each marker by a
uniform inflation factor determined by evaluating the distribution of test statistics across all
markers. However, this approach does not factor in that some markers will have greater
differences in alleles frequencies across different ancestral populations than others. Thus, the
uniform adjustment would under correct for markers with large differences in allele frequencies
across populations and over correct for markers with relatively small differences in allele
frequencies across populations. Structured association is based on assigning individuals to
subpopulations using a model-based Bayesian clustering algorithm implemented in the
program STRUCTURE, and then carrying out all analyses conditional on the inferred
assignments. Given the computational complexity of this approach, structured association is
limited to a relatively small number of ancestral informative markers – markers that have large
allele frequencies across measured populations. The primary concerns regarding this approach
are the reliance on a relatively small number of markers to differentiate between populations,
the adequacy of a modest number of markers to differentiate between populations that have
not been previously extensively studied, and the sensitivity of the approach to the assumed
number of clusters (which is somewhat arbitrarily chosen by the user). The utilization of
principal components, a data reduction method designed to capture most of the variability
across all SNPs using a relatively small number of independent continuous variables, allows
the inclusion of a genome-wide panel of markers to measure and account for systematic
differences in ancestry is becoming an increasingly popular analytic approach for identifying
population substructure and for controlling for it in genetic association studies. This method
has the benefit of being computationally efficient and allows the inclusion of hundreds of
thousands of genetic markers, making the a priori choice of ancestry informative markers in
GWA studies unnecessary.
Critical to the validity of case-control genetic association study results is the ability of analytic
methods to account for population stratification, particularly for SNPs in regions of selection.
Despite the recognition of this problem, empirical and simulation-based studies designed to
evaluate the impact of population stratification, after application of methods designed to control
for it, have been somewhat limited. It should be noted that all of the described analytic
approaches failed to resolve the observed population stratification in a case-control sample of
Americans of European origin that were selected for extreme values of height (6,22,23). For
example, in the study by Campbell and colleagues (6), height and allele frequencies at the
lactase gene (LCT [MIM 603202]) varied considerably from northwestern to southeastern
Europe and a false-positive association was found linking the lactase gene with height in this
sample. Results across a number of studies suggest that analytic methods designed to address
confounding will dramatically reduce the number of false positives due to population
stratification but will not completely eliminate the problem (6). A recent European GWA study
on Rheumatoid arthritis found evidence for spurious association at LCT and IRF4, two regions
that are known to be highly selected in European populations (24). The application of both
principal components and STRUCTURE, in this study, reduced the confounding at these two
regions, but did not remove the effects entirely. Regardless, if the causal polymorphisms are
highly correlated with underlying population structure (e.g. because of natural selection), it
will not be possible to distinguish between true and false positives statistically, and any attempt
to remove the population structure will reduce the power to detect truly associated markers.
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The recent WTCCC GWA study found only modest evidence of over-dispersion (λ ranging
from 1.03-1.11 for the seven diseases evaluated) in their association trend test statistics, despite
strong evidence for highly discrepant allele frequencies at SNPs in 13 different chromosomal
regions between control samples collected from 12 different geographical regions in the UK
(1). In this study, both cases and controls were ascertained throughout the UK; there was little
evidence for confounding due to population stratification when comparing case allele
frequencies to that of controls even prior to incorporating analytic methods to control for this
effect. On the other hand, the observed evidence for numerous genomic regions under apparent
selective pressure in the WTCCC study could cause some concern regarding the validity of
case-control genetic association study results for a subset of SNPs in the genome, especially
when cases and controls are not ascertained from the same geographical region.
Family-based samples and family-based genetic association studies
For many complex diseases, a large number of pedigrees with multiple affected relatives have
been recruited in the past for genetic linkage studies. While the ability of genetic linkage studies
to identify regions that contain susceptibility variants for complex diseases may be limited due
to heterogeneity, reduced penetrance, and phenocopies (25), these families may still be
extremely useful for association testing. Of note, DNA samples from thousands of families
with hereditary prostate cancer have already been collected for linkage studies. These families
have extensive clinical information with respect to prostate and other cancers in the probands
and other family members that may prove invaluable when trying to understand the complex
genetic etiology of the disease and offer the unique opportunity to evaluate parent-of-origin
effects, or imprinting, that cannot be evaluated in studies of unrelated cases and controls.
Typical genetic case-control association studies use unrelated population-based cases and
controls. Several theoretical and simulation studies (26-29) have demonstrated that greater
power can be achieved in genetic case-control association studies by selecting cases from
families with multiple cases over selecting unrelated cases with no family history of the disease.
Empirical results from prostate cancer genetic association studies support these conclusions.
Specifically, we observed stronger effects of 8q24 variants in our prostate cancer cases from
high-density hereditary prostate cancer families than in unrelated prostate cancer cases
collected independent of family history (30). A recently completed GWA study for prostate
cancer using cases diagnosed prior to age 61 or with a family history of disease was
tremendously successful in not only strongly replicating the results from previous GWA studies
(namely, variants associated with prostate cancer on 8q and 17q) but also in identifying seven
new regions that harbor genetic variants significantly associated with the disease (16). This
study demonstrates the considerable power that can be gained by studying cases, such as those
collected through linkage studies, which are enriched for carrying genetic susceptibility
variants.
While considerable power can be gained using familial cases in case-control association
studies, the use of familial cases in the case-control study design does not protect the
conclusions from the impact of population stratification. An alternative study design to case-
control designs is family-based association. Family-based association methods evaluate
whether particular alleles are transmitted from parents down to affected offspring in a
proportion that is different than expectation under the null hypothesis of no association between
marker and disease. Because these methods utilize non-transmitted alleles from the same
parents as the control sample, these methods are not susceptible to population stratification.
The transmission disequilibrium test was originally proposed for a parent-parent-affected
offspring design (31), but has been extended to include siblings discordant for the disease under
study and general family-designs (32,33). Since many of the diseases of interest typically have
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a late age of onset, the consequential unavailability of parents has made these more general
forms of the transmission disequilibrium test popular.
While family-based study designs offer protection from false positives due to population
stratification, they have not been the design of choice for many due to the relative inefficiency
of the design. Specifically, it is widely accepted that collecting family-based samples is
considerably more expensive than collecting a sample of unrelated cases and controls. In
addition, the matching of transmitted with non-transmitted alleles from the same family reduces
statistical power. Consequently, to get the same power as a case-control study design, a larger
number of family-based samples will have to be ascertained and genotyped. This increased
cost has motivated the development of statistical techniques to account for population
stratification in case-control designs. However, as noted above, these statistical methods are
not perfect and cannot completely remove doubt regarding the validity of any single association
result in a case-control design. Many family-based samples have already been collected
through linkage studies, thus the additional cost of collecting these family-based samples is
often not a major concern. The additional costs associated with having to genotype a
significantly larger number of samples to achieve equivalent power still likely renders
performing a GWA study on family-based samples (even on previously collected samples)
inefficient. Unique to nuclear families when both parents are available for genotyping, the cost
of performing a GWA study can be mitigated by genotyping the offspring on a significantly
reduced number of SNPs and imputing (with a high degree of accuracy) the remaining SNPs
in the offspring by using the linkage phase on the subset of SNPs typed for all family members.
Family-based studies may be ideal for validating previously identified genetic risk factors,
Follow-up case-control studies typically have to perform extra genotyping for a large number
of ancestry informative markers (which would not need to be genotyped for a family-based
study) in an attempt to control for population stratification. In addition, while GWA studies
require a strict correction for multiple testing to account for the hundreds of thousands of
genetic markers analyzed, follow-up studies require a much less stringent significance
threshold given the focused a priori hypotheses. Combining these factors with the fact that
large family-based samples have already been collected suggests family-based association tests
can be an efficient and useful strategy for validating previously identified genetic susceptibility
markers. Further studies need to be performed to evaluate the relative power of family-based
association analyses compared to case-control designs when utilizing methods that correct for
population stratification. In particular, it is important to evaluate the impact of poorly matched
case-control samples, over correction for ancestry, and causal markers that are strongly
associated with population structure. Regardless of these findings, family-based association
methods are clearly useful to dissect true association from false association due to population
stratification.
We performed a transmission disequilibrium test for SNPs at Regions 1, 2 and 3 of 8q24 in
168 HPC families of European ancestry using the FBAT program (30). As shown in Table 2,
risk alleles of one SNP in Region 2 was significantly over-transmitted from parents to affected
men (P = 0.003). However, this was not the case for risk alleles of SNPs in Regions 1 and 3,
despite significant differences in allele frequencies observed for these SNPs between these
same familial cases and a sample of unrelated screened controls. Results from the family-based
transmission tests suggested that SNPs at Region 2 confer prostate cancer risk while creating
some concern that the association between prostate cancer and SNPs in the other two regions
may be due to population stratification (perhaps a consequence of higher African ancestry at
8q24 in prostate cancer cases than controls).
From a clinical standpoint, common susceptibility markers found in primarily non-familial
cases needs to be evaluated in familial cases. Individuals with a strong family history of a
Lange et al. Page 7













disease are most likely to seek genetic counseling and subsequent genotyping for genetic risk
factors for that disease. While family-based samples collected for linkage analyses are a non-
representative collection of cases that are more likely to carry genetic susceptibility than
population based cases, these existing family data can be useful to assess how important these
risk factors are in individuals most likely to seek medical prevention. Finally, for diseases such
as prostate cancer, genetic heterogeneity has made the identification of rare highly penetrant
mutations through linkage analysis difficult. Evaluating the role of common variants in
hereditary prostate cancer families will be critical in determining whether an accumulation of
common risk variants is responsible for hereditary prostate cancer or whether there exist a
number of rare high penetrant mutations that explains the significant clustering of the disease
within families.
Conclusion
We believe that cautious interpretation and continued attention to population stratification as
a potential confounder remains a critical issue in case-control genetic association studies in
spite of the recent advances in analytical methods designed to address this potential problem.
Family-based association study designs are largely impervious to the effects of population
stratification in terms of controlling the rate of false positive tests. Family-based samples are
readily available from linkage studies that have collected DNA samples from thousands of
pedigrees that have multiple cases of disease. Despite some clear advantages, including higher
rates of genetic susceptibility variants in familial cases, these family samples have been largely
ignored in GWA studies. Family-based association study designs have not been routinely used
because of concerns that they are not as statistically powerful or cost effective as case-control
designs. These concerns argue that family-based association methods are not ideal for SNP
discovery. However, family-based association studies may be vital in teasing out which
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Geographic variation of allele frequencies in the genome. A: Copy of the Figure 2A in the
paper (1) showing P values for the 11-d.f. test for differences in SNP allele frequencies between
12 broad geographical regions in Great Britain. Green dots indicate SNPs with a P value < 1
× 10−5. Cluster of highly significant SNPs are found in several genomic regions, including
4p14 that contains TLR6-1-10 gene cluster. B: Association test between prostate cancer risk
and a SNP at 5′UTR of TLR1 gene (rs5743551) in the CAPS (Cancer of Prostate in Sweden)
study population. Statistical association was found in CAPS (P = 0.0009). However, significant
difference in allele frequencies between Region 1 (Northern part of Sweden) and Region 2
(Central part of Sweden) were also found, although the minor allele was always higher in cases
than in controls in both regions.
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Estimated percent of African ancestry in the genome among prostate cancer cases and controls
in African Americans. Plot was made based on Supplementary Table 6 of published paper
(17). Higher percent of African ancestry in cases than controls was found across the genome.
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